Please Note: This trial is no longer enrolling new participants
A randomized study of TPST-1120 with atezolizumab plus bevacizumab versus placebo with atezolizumab plus bevacizumab in patients with unresectable or metastatic HCC not previously treated with systemic therapy.
| Protocol No. | CTO-TPST-1120-301 | Scope | National |
|---|---|---|---|
| Principal Investigator | Anita Turk | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase III |
